Skip to main content
Oryzon Genomics S.A. logo

Oryzon Genomics S.A. — Investor Relations & Filings

Ticker · ORY ISIN · ES0167733015 LEI · 95980063R15RDF29DK13 MC Manufacturing
Open in API
Filings indexed 142 across all filing types
Latest filing 2025-01-25 AGM Information
Country ES Spain
Listing MC ORY

About Oryzon Genomics S.A.

https://www.oryzon.com/en

Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.

Recent filings

Filing Released Lang Actions
Convocatoria de la Junta General Extraordinaria de accionistas de Oryzon Genomics, S.A.
AGM Information Classification · 98% confidence The document is a formal announcement titled "CONVOCATORIA DE LA JUNTA GENERAL EXTRAORDINARIA DE ACCIONISTAS 2025 DE ORYZON GENOMICS, S.A." (Call for the Extraordinary General Shareholders' Meeting 2025). It details the date, time, location, and the full agenda (ORDEN DEL DÍA) for the meeting, which includes items like the appointment/re-election of directors and approval of capital structure changes (issuance of convertible bonds, capital increases). It also outlines shareholder rights regarding information requests, proposal submissions, and procedures for remote attendance and voting. This content is characteristic of a notice or proxy material related to a shareholder meeting, specifically the formal call for the meeting itself, which aligns best with the 'AGM Information' category, as it precedes the actual meeting and details the proceedings and agenda.
2025-01-25 Spanish
Convocatoria de la Junta General Extraordinaria de accionistas de Oryzon Genomics, S.A.
AGM Information Classification · 98% confidence The document is a formal communication from ORYZON GENOMICS, S.A. announcing the convocation of an Extraordinary General Shareholders' Meeting ('Junta General Extraordinaria de Accionistas') scheduled for February 28, 2025. It explicitly states that the full text of the convocation and related documentation are attached or will be made available. This type of announcement, which calls for a shareholder meeting and provides related materials, strongly aligns with the purpose of materials shared during or in preparation for a General Meeting. While it is an announcement of a meeting, the content is directly related to the meeting itself, making 'AGM Information' (AGM-R) the most appropriate category, as it covers presentations and materials shared during the AGM, which includes the formal convocation notice.
2025-01-25 Spanish
Convocatoria de la Junta General Extraordinaria de accionistas de Oryzon Genomics, S.A.
AGM Information Classification · 98% confidence The document is a formal communication from ORYZON GENOMICS, S.A. announcing the convocation of an Extraordinary General Shareholders' Meeting ('Junta General Extraordinaria de Accionistas') scheduled for February 28, 2025. It explicitly states that the full text of the convocation and related documentation are attached or will be made available. This type of announcement, which calls for a shareholder meeting and provides related materials, strongly aligns with the purpose of materials shared during or in preparation for a General Meeting. While it is an announcement of a meeting, the content is directly related to the meeting itself, making 'AGM Information' (AGM-R) the most appropriate category, as it covers presentations and materials shared during the AGM, which includes the formal convocation notice.
2025-01-25 Spanish
Solicitud de conversión de bonos T3-1
Capital/Financing Update Classification · 98% confidence The document is a formal communication from ORYZON GENOMICS, S.A. titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It explicitly references Spanish securities law (Ley 6/2023) and details a specific financial transaction: the conversion of convertible bonds into new shares (805,083 new shares) and the subsequent request for admission to trading on Spanish stock exchanges. This action directly relates to changes in the company's capital structure and financing activities. This aligns best with the 'Capital/Financing Update' category (CAP), as it details the execution of a financing program resulting in new share issuance.
2024-11-21 Spanish
La sociedad remite información sobre los resultados del tercer trimestre de 2024
Earnings Release Classification · 99% confidence The document explicitly states it is communicating 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) regarding the results for the third quarter of 2024 ('resultados correspondientes al tercer trimestre de 2024'). It includes key financial highlights (R&D investment, net result, cash position) and extensive operational updates on clinical trials (vafidemstat and iadademstat programs). This structure—a brief announcement followed by detailed operational and financial commentary for a specific period shorter than a year—is characteristic of an Interim/Quarterly Report (IR). Although it mentions a press release is attached, the document itself contains the comprehensive results and management discussion, making it the report content rather than just a publication announcement (RPA). Since it covers Q3 2024, it is not the Annual Report (10-K). Q3 2024
2024-10-24 Spanish
Oryzon recibe el acta de la reunión de Fin-de-Fase II con la FDA para vafidemstat en Trastorno Límite de la Personalidad
Legal Proceedings Report Classification · 99% confidence The document is an official communication from ORYZON GENOMICS, S.A. (ORYZON) titled "OTRA INFORMACIÓN RELEVANTE" (Other Relevant Information), dated October 1, 2024. It announces that the company received the minutes from the End-of-Phase II meeting with the US FDA regarding the drug vafidemstat for Borderline Personality Disorder (BPD). The text explicitly states, "Se adjunta la nota de prensa que será distribuida en el día de hoy" (The press release to be distributed today is attached). The bulk of the document is the attached press release detailing the positive feedback from the FDA supporting the initiation of Phase III trials (PORTICO-2). This structure—a brief regulatory filing announcing the release of detailed information (a press release/update)—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content is a specific, material update about clinical trial progress and regulatory feedback, and it is presented as an announcement with an attached press release, it is best classified as an announcement of material information. Given the options, this is a significant regulatory/material update that is not a standard periodic report (10-K, IR) or a transcript (CT). It is an announcement of a major development, which often falls under general regulatory filings or specific announcements. Since it is an announcement regarding clinical/regulatory progress, and not a formal financial report, 'RNS' (Regulatory Filings) is the most appropriate general category for material, non-standard announcements, although 'RPA' (Report Publication Announcement) is also plausible as it announces the publication of the press release. Given the nature of the content (FDA feedback, next steps for Phase III), it is a key regulatory update, making RNS a strong fit, or potentially a specific type of material information disclosure. However, since it is a formal communication mandated by securities law (Article 227 of Law 6/2023) announcing material news, and it is not a specific financial report, RNS is the best fit as a general regulatory disclosure.
2024-10-01 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.